Research peptide stores sell these compounds as research chemicals, not as medicines. Some of the same ingredients are in approved medicines, but an approval covers one maker's finished product. The listings on PeptidesGrid are sold as research chemicals, not as the approved products named below.
This page gives the regulatory status of all 54 peptides on the site, checked Sep 25 and 26, 2026. It is a status check only. It is not medical advice and not advice to use anything.
How we checked
On Sep 25, 2026 we searched Drugs@FDA, the European Medicines Agency (EMA) medicines list and Health Canada's Drug Product Database for every ingredient. For products still in trials we read the companies' own releases. For approvals in other countries we checked company filings and Vidal, a Russian drug reference that lists each product's registration, with its Belarus edition. We also checked France's ANSM medicines database, Japan's PMDA, Italy's AIFA medicines database, India's CDSCO list of new drugs and EMA lists of nationally authorised products. We did not search every country's register. We checked the eight peptides added on Sep 26, 2026 (Thymalin, Gonadorelin, Adipotide, Testagen, Cartalax, Cardiogen, PNC-27 and Prostamax) on that day.
Status of all 54 peptides
| Peptide | Status, checked Sep 25 or 26, 2026 |
|---|---|
| Approved in the US, EU or Canada | |
| Tirzepatide | Mounjaro and Zepbound, from Eli Lilly. Approved by the FDA (Mounjaro, 2022; Zepbound, 2023), the EMA (Mounjaro, 2022) and Health Canada (Mounjaro, Zepbound). |
| Semaglutide | Ozempic, Wegovy and Rybelsus, from Novo Nordisk. Approved by the FDA, the EMA and Health Canada. The EMA also approved Kayshild (Novo Nordisk) in March 2026. Health Canada approved generic semaglutide from Dr. Reddy's (announced April 28, 2026), then from Apotex (including Sevmia), Aspen and Sandoz. |
| Tesamorelin | Egrifta, from Theratechnologies. FDA, 2010. The EU application was withdrawn in 2012. Health Canada's listings were cancelled in 2022 and 2023. |
| SS-31 | Elamipretide, sold as Forzinity by Stealth BioTherapeutics, now Mighty Therapeutics. FDA accelerated approval (an approval based on early evidence, which the company must confirm in later studies), September 19, 2025. Not approved in the EU or Canada. |
| PT-141 | Bremelanotide, sold as Vyleesi by Cosette Pharmaceuticals. FDA, 2019. Not approved in the EU or Canada. |
| Oxytocin | Pitocin, from Par Health, is FDA approved. Other makers' oxytocin injections are approved in the US and Canada. |
| Melanotan I | Afamelanotide, sold as a 16 mg implant (Scenesse) by Clinuvel. Approved by the EMA (2014), the FDA (2019) and Health Canada (2026). Research vendors sell the peptide in vials, which is not the approved product. |
| Approved for people elsewhere, not currently by the FDA, EMA or Health Canada | |
| Mazdutide | Xinermei, from Innovent Biologics under a license from Eli Lilly. China's NMPA approved it on June 27, 2025, with a second approval on September 19, 2025. |
| Thymosin Alpha-1 | Thymalfasin, sold as Zadaxin by SciClone Pharmaceuticals. SciClone's annual report for 2004 lists approvals in over 30 countries, mainly in Asia, the Middle East and Latin America. |
| Selank | Selank, from Peptogen, is registered as a medicine in Russia. |
| Semax | Semax, from Peptogen, is registered as a medicine in Russia. An FDA advisory committee voted on compounding it in July 2026. That is not an approval; see below. |
| DSIP | Deltaran, from the KOMKON research center, contains DSIP. It is registered in Russia (registration LP-003849). An FDA advisory committee voted against compounding it, as emideltide, in July 2026; see below. |
| GHRP-2 | Pralmorelin, sold in Japan as GHRP Kaken 100 (Kaken Pharmaceutical) for diagnosing growth hormone deficiency. Approved in Japan in 2004. |
| VIP | Aviptadil, combined with phentolamine as Invicorp (Evolan Pharma), is authorised nationally in Germany, Denmark, Finland, France, Norway, Sweden and Northern Ireland, according to an EMA list from October 2022. Sweden still lists it. In April 2022 India's regulator gave a single-ingredient aviptadil injection a restricted emergency approval. Not approved by the FDA, the EMA or Health Canada. |
| Glutathione | Glutathione injections are approved medicines in Japan (Tathion, from Choseido Pharmaceutical) and Italy (TAD, from Biomedica Foscama, and others). Not approved by the FDA, the EMA or Health Canada. Its oxidised form is a minor ingredient of approved eye irrigation solutions such as BSS Plus. |
| Thymalin | Thymalin, an extract of cattle thymus, is registered as a prescription medicine in Russia (Samson-Med) and Belarus (Belmedpreparaty). It is an extract, not one defined peptide, so vials research vendors sell under the name are not that product. Not approved by the FDA, the EMA or Health Canada. |
| Gonadorelin | Authorised for people in France as Lutrelef and LHRH Ferring (Ferring), per the ANSM database (Lutrelef, LHRH Ferring). The FDA approved it for people as Factrel (1982) and Lutrepulse (1989), both since discontinued. The only gonadorelin products the FDA lists for use today are injections for cattle. No EMA authorisation. |
| In clinical development | |
| Retatrutide | Eli Lilly, phase 3 (the large trials run before a company applies for approval). On July 23, 2026 Lilly said it planned to apply for US approval in Q1 2027. |
| Cagrilintide | Novo Nordisk, phase 3. On September 16, 2025 Novo said it would move it into its own phase 3 program, RENEW. |
| CagriSema | Novo Nordisk applied for FDA approval on December 18, 2025. Its Q2 2026 report (August 4, 2026) expected the US decision in Q4 2026. |
| Survodutide | Phase 3, run by Boehringer Ingelheim, which licensed it from Zealand Pharma. On August 13, 2026 Zealand Pharma said results from SYNCHRONIZE-2 would be presented at the EASD meeting, September 28 to October 2, 2026. |
| Not currently approved anywhere we could find | |
| BPC-157, TB-500, KPV, MOTS-c, Epitalon | No approved product found. An FDA advisory committee voted on compounding them in July 2026. That is not an approval; see below. |
| GHK-Cu, Ipamorelin, CJC-1295 no DAC, CJC-1295 DAC, HGH Frag 176-191, AOD-9604, Kisspeptin-10 | No approved product found. |
| NAD+ | Not a peptide. No approved NAD+ product found. |
| Melanotan II | No approved product found. A different peptide, afamelanotide (melanotan I), is approved as Scenesse (Clinuvel) in the EU, the US and Canada. |
| Sermorelin | Once approved in the US as Geref (EMD Serono). The maker stopped selling it, and the FDA withdrew the approvals in 2009. |
| BPC-157 + TB-500, GLOW, KLOW, CJC-1295 + Ipamorelin | Vendor blends. No approved product contains these mixes. |
| LL-37, ARA-290, Pinealon, FOXO4-DRI, GHRP-6, Hexarelin | No approved product found. |
| IGF-1 LR3 | No approved product found. Mecasermin (Increlex), which is unmodified IGF-1, is approved by the FDA (2005), the EMA (2007) and Health Canada; it is a different molecule. |
| SNAP-8 | Acetyl octapeptide-3, listed as a cosmetic ingredient in the EU. Not approved as a medicine. |
| Adipotide, PNC-27, Testagen, Cartalax, Prostamax | No approved product found. |
| Cardiogen | No approved product found. CardioGen-82, an FDA-approved rubidium Rb 82 generator from Bracco used in heart imaging, is an unrelated product with a similar name. |
What "approved" means here
- An approval covers one product from one maker. The regulator reviews that maker's formula, dose form, factory and label. It does not cover the same ingredient made or sold by anyone else. A research vial of tirzepatide is not Mounjaro or Zepbound.
- Generics need their own approval. Health Canada approved each generic semaglutide product separately. In the US, Apotex's generic semaglutide has only a tentative approval, dated April 7, 2026, and Drugs@FDA lists no marketing status for it. A tentative approval means the FDA found the product meets its standards, but it cannot be sold yet, usually because of patents or exclusivity.
- Compounding votes are not approvals. On July 23 and 24, 2026, an FDA advisory committee reviewed seven peptides for the list of substances pharmacies may use to compound, meaning to mix medicines for individual patients. It voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, and against emideltide (DSIP). The FDA's briefing on TB-500 for that July 2026 meeting describes it as a seven-amino-acid fragment of thymosin beta-4. A product sold as TB-500 may be that fragment or full thymosin beta-4, so check what a listing says it contains. PeptidesGrid's TB-500 page leaves out listings sold as that fragment, or whose own page describes it (Ac-LKKTETQ, amino acids 17 to 23). But some listings it compares call their product a fragment of thymosin beta-4 without saying which part, so PeptidesGrid cannot tell whether a given vial is the substance the committee voted on. The pharmacists' group NCPA notes that the votes "are not binding on the FDA" and that pharmacies cannot compound them until a final rule is in place. Even a final listing would not approve any product.
- Approvals can end. Sermorelin's US approvals were withdrawn in 2009, and tesamorelin's Canadian listings were cancelled.
- "EU" here means an EU-wide authorization from the EMA. Single EU countries can also approve medicines on their own. We name those only where we found them (glutathione in Italy, gonadorelin in France and Invicorp in several countries); we did not search every national register. Italy's medicines agency, AIFA, also lists thymosin alpha-1 (Zadaxin, authorised since 1996) and oxytocin (Syntocinon, from Alfasigma) as authorised medicines (read Sep 26, 2026).
Re-check dates:
- the FDA decision on CagriSema, which Novo's report of August 4, 2026 expected in Q4 2026;
- survodutide's SYNCHRONIZE-2 results at EASD, September 28 to October 2, 2026, and any filing that follows;
- any final FDA rule on the compounding list;
- Lilly's planned US filing for retatrutide in Q1 2027.
Status checked Sep 25 and 26, 2026 against Drugs@FDA, the EMA medicines list, Health Canada's Drug Product Database, Vidal (Russia and Belarus), France's ANSM database, PMDA, AIFA, CDSCO and company releases. Approvals change, so check the regulator's own record. Last reviewed Sep 27, 2026.